Synopsis: Wanbury Ltd hit an upper circuit of 20% after unveiling its Tanuku API facility, producing four high-value APIs targeting Rs. 100 crore revenue in FY27, tapping a Rs. 5,000 crore global market and strengthening its domestic and international footprint.
This company is in the business of pharmaceutical and related activities, including research and has a wide presence across major therapeutic categories like cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastrointestinal, anti-inflammatory, & analgesics is now in the spotlight after it rose by 12% following the unveiling of its facility.
With a market capitalisation of Rs. 614 cr, the shares of Wanbury Ltd are currently trading at Rs. 176 per share, hitting an upper circuit of 20% in today’s market session to Rs. 195.70, up from its previous close of Rs. 163.10 per share. The stock has seen significant losses, falling 16% over the past year, 20% year-to-date, 23% in the last six months, and 21% in the past month.
News
Wanbury Limited has announced the commercial production of four new high-value Active Pharmaceutical Ingredients (APIs) at its state-of-the-art Tanuku facility in Andhra Pradesh. The facility will cater to both domestic and global markets, strengthening the company’s API portfolio and addressing strong healthcare demand.
The new APIs include Anti-Tussive, Anti-Diabetic, Anti-Coagulant, and Anti-Depressant APIs, which are expected to generate incremental revenues of over Rs. 100 crore in FY 2026-27, with a target to meet rising global demand for these therapeutic segments. The global market for these high-value APIs is estimated at around Rs. 5,000 crore.
The company’s expansion underscores its commitment to enhancing production capacity and delivering high-quality pharmaceutical intermediates. This milestone is part of Wanbury’s broader strategy to capture growth opportunities in global API markets, fuelled by robust demand for branded formulations and intermediates.
Wanbury Ltd has a strong presence in the API global market and domestic branded Formulation, with its API being exported to over 50 countries and has a Pan-India Formulation presence. The company has USFDA & EUGMP-approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).
The API product portfolio includes Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine, Ketamine Hydrochloride and various other products in the pipeline. The company’s clients include some of the leading global generic players.
The company has a ROCE of 36.7 percent and a ROE of 76.5 percent, with a PEG ratio of 0.18. It has delivered strong profit growth at a CAGR of 31 percent over the past five years.
A consistent pattern of growth in API (Active Pharmaceutical Ingredient) sales has been maintained over the last few years and there has been only a slight change to the revenue mix over the same period.
API sales have shown a strong upward trend climbing from 356 units in FY21 to 530 units in FY25. There has been a fall in the share of total revenues attributable to sales of APIs, however the share amounts remained strong at 91% in FY21 and 88% in FY25. The product Metformin contributes 50 percent of all sales made in FY25, with the second largest product being Sertraline contributing 40% of total sales made in FY25.
Tramadol has a smaller contribution to total API revenues at 6%, while all other APIs collectively contributed to 4% of total API revenues in FY25. This information demonstrates that Metformin and Sertraline are essential products for the company to generate API revenue, which suggests that these two products are the primary drivers of overall performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma Stock Hits 20% Upper Circuit as It Begins Commercial Production at Its Tanuku API Facility appeared first on Trade Brains.